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Type-2 diabetes results from the development
of insulin resistance and a concomitant impair-
ment of insulin secretion. Recent studies place
altered mitochondrial oxidative phosphoryla-
tion (OxPhos) as an underlying genetic element
of insulin resistance. However, the causative or
compensatory nature of theseOxPhos changes
has yet to be proven. Here, we show that
muscle- and liver-specific AIF ablation in mice
initiates a pattern of OxPhos deficiency closely
mimicking that of human insulin resistance,
and contrary to current expectations, results in
increased glucose tolerance, reduced fat mass,
and increased insulin sensitivity. These results
are maintained upon high-fat feeding and in
both genetic mosaic and ubiquitous OxPhos-
deficient mutants. Importantly, the effects of
AIF on glucosemetabolism are acutely inducible
and reversible. These findings establish that
tissue-specific as well as global OxPhos defects
in mice can counteract the development of
insulin resistance, diabetes, and obesity.
INTRODUCTION
Type-2 diabetes mellitus (T2DM), with over 6 million new
cases reported per year, currently represents one of the476 Cell 131, 476–491, November 2, 2007 ª2007 Elsevier Inc.world’s chief economic and health care challenges. Asso-
ciated in >50% of cases with obesity, diabetes results
from an imbalance in insulin secretion and peripheral
insulin responsiveness. While a correlative involvement
for mitochondria in both of these processes has long
been recognized, their exact etiological contribution to-
ward diabetes and obesity remains unclear (Lowell and
Shulman, 2005).
Mitochondrial dysfunction in humans is manifest as
a variety of disorders with clinical outcomes largely
dependent on the magnitude and tissue distribution of
the impairment (Lane, 2006; Wallace, 1999). A number of
recent studies have implicated impaired skeletal muscle
OxPhos in the etiology of insulin resistance proposing
a mechanism for the development of diabetes and obe-
sity (Lowell and Shulman, 2005; Wisløff et al., 2005; Ra-
bol et al., 2006). Microarray expression analyses have
highlighted the coordinate downregulation of mitochon-
drial genes controlled by the regulators of mitochondrial
biogenesis peroxisome proliferator-activated receptor
g coactivator 1a (PGC-1a) and nuclear respiratory factor
1 (NRF-1) in biopsies from insulin resistant subjects (Moo-
tha et al., 2003; Patti et al., 2003). In addition, in vivo nu-
clear magnetic resonance studies have revealed a strong,
inverse correlation between OxPhos function and insulin
resistance in skeletal muscle in human patients (Petersen
et al., 2003, 2004). By contrast, more recent work in human
diabetic patients have both questioned the consistency of
this correlation (Boushel et al., 2007) and extended correla-
tions to include OxPhos changes in the liver and fat (Dahl-
man et al., 2006; Misu et al., 2007). Despite the profound
implications of these findings for diabetes and obesity, the
causative or compensatory nature of primary mitochondrial
OxPhos deficiencies remains an enigma.
We have previously shown that conditional deletion of
the mitochondrial flavoprotein apoptosis inducing factor
(AIF) in mice can initiate progressive OxPhos dysfunction
(Joza et al., 2005; Susin et al., 1999). AIF was originally
identified as a mitochondrial protein involved in cell death
(Susin et al., 1999; Wissing et al., 2004). However, muta-
tion analysis in numerous model organisms has now es-
tablished that the primary physiological role of AIF is main-
tenance of a fully functional respiratory chain (Cheung
et al., 2006; Joza et al., 2005; Vahsen et al., 2004). When
deleted, this inner-mitochondrial membrane-associated
protein leads to a progressive loss of respiratory chain
function and activity (Joza et al., 2005; Vahsen et al.,
2004). Here, we test and exploit the respiratory-chain-
stabilizing properties of AIF to generate models of pro-
gressive OxPhos deficiency and ask the question whether
primary defects in mitochondrial respiration cause insulin
resistance, diabetes, and/or obesity. Our data provide
novel insight into the role of AIF in respiratory chain func-
tion, implicate AIF as a prominent regulator of obesity and
diabetes susceptibility, and provide genetic evidence that
tissue-specific and global reductions in OxPhos can
induce a state of insulin sensitivity and resistance to met-
abolic disease.
RESULTS
Generation of Muscle- and Liver-Specific AIF
Knockout Mice
We previously reported that conditional deletion of AIF
in mice initiates a progressive reduction in OxPhos (Joza
et al., 2005; Vahsen et al., 2004). Since our initial report,
the conditional AIF line has been crossed >8 times onto
the C57BL/6 background, reducing the severity and
slowing the kinetics of the mitochondrial deficiency trig-
gered by AIF deletion. Crossing the conditional AIF mice
(Aifflox/flox) to those bearing a transgene for cre-recom-
binase under control of either the muscle creatine kinase
promoter (Mck-cre) (Bruning et al., 1998) or the liver albu-
min promoter (Alb-cre) (Postic et al., 1999), we generated
mice displaying muscle- or liver-specific OxPhos defi-
ciencies (AIFflox/y; Mck-cre/+ and AIFflox/y; Alb-cre/+ re-
spectively). Both MAIFKO (muscle-specific AIF knockout)
and LAIFKO (liver-specific AIF knockout) pups were
born healthy, viable, and at normal Mendelian ratios
(Figures 1A and 1B). PCR and western blotting con-
firmed efficient deletion of the AIF allele specifically in
striated muscle in MAIFKO mice and in the liver in LAIFKO
animals (Figures 1C and 1D). Morphological, histologi-
cal, and serum analyses to assess muscle and liver
condition revealed no abnormalities at 8 weeks of age in
either set of mice (Figures 1E and 1F; see Figures S1A–
S1C in the Supplemental Data available with this article
online).Muscle- and Liver-Specific AIF Knockout
Mice Exhibit Defective Mitochondrial
Oxidative Phosphorylation
In order to test whether a primary OxPhos deficiency plays
a causal role in insulin resistance, several criteria must be
met. First, due to the importance of the respiratory chain to
cellular function, the perturbations in OxPhos gene ex-
pression and function must be modest. Second, due to
the distinct roles of respiratory chain subunits and the
broad changes reported in human studies, the model
should affect the OxPhos pathway in as generalized
a fashion as possible (Mootha et al., 2003; Patti et al.,
2003).
To assess the suitability of our model, we performed mi-
croarray analyses on hindlimb muscle (MAIFKO) and liver
(LAIFKO) tissue obtained from 8-week-old AIF mutant
mice and their littermate controls. Comparison with the
previously published data sets linking OxPhos downregu-
lation in muscle to insulin resistance in humans (Mootha
et al., 2003; Patti et al., 2003) yielded >85% overlap in
coordinate OxPhos expression pattern between each
MAIFKO and LAIFKO data sets and those of human insulin
resistant subjects (Figures 1G and 1H; Table S1). Included
were downregulation of 90% of the detectable NRF-1
regulated homologs and 100% of the detectable PGC-
1a-responsive mouse homologs in MAIFKO mice (Table
S1). Paralleling data from type 2 diabetic human subjects
(Mootha et al., 2003; Patti et al., 2003), the majority of the
observed reductions in OxPhos gene expression were
modest in extent and highly coordinated (Figure 1I). Both
the MAIFKO and LAIFKO microarray data sets were sub-
ject to gene-ontology-based analyses of 271 cellular path-
ways curated from the KEGG and BioCarta databases
(Mootha et al., 2003; Tomfohr et al., 2005). Specific in-
activation of AIF produced the statistically most robust
modulation of the Oxidative Phosphorylation Pathway in
each tissue data set (Figure 1J; Table S2). Inconsequential
effects were observed on the expression of numerous cell
death pathways. Further, ultrastructural and nucleic acid
analyses revealed no obvious alteration in mitochondrial
morphology or tissue mitochondrial DNA content (Figures
S2A and S2B; Figure S3A). Thus, MAIFKO and LAIFKO
mice display a tissue-specific decrease in OxPhos gene
expression reminiscent of that observed in muscle of
insulin resistant patients.
We next tested whether these changes in respiratory
gene expression were manifest on protein and functional
levels using western blot (Figure 2A) and spectrophoto-
metry/polarography of isolated mitochondria (Figure 2B).
Corroborating our previous findings (Joza et al., 2005;
Vahsen et al., 2004), complexes I and IV of the respiratory
chain were functionally affected by loss of AIF expression
in muscle, while liver-specific deletion of AIF was manifest
primarily as a combined complex I and complex V defi-
ciency (Figure 2B). Consistent with data from humans
(Petersen et al., 2003), expression of muscle respiratory
chain components decreased with age in both control
and mutant MAIFKO animals (Figures S3B and S3C).Cell 131, 476–491, November 2, 2007 ª2007 Elsevier Inc. 477
Figure 1. Muscle- and Liver-Specific AIF
Knockout Mice Display Normal Tissue
Morphology and Exhibit a Deficiency in
OxPhos Gene Expression
(A) Muscle-specific (MAIFKO) and (B) liver-
specific AIF knockout mice (LAIFKO) mice
develop and grow normally until at least 2
months of age. (C) Deletion of loxP flanked
exon 7 of the Aif-allele (Aifflox) by Mck- or Alb-
driven transgenic cre recombinase result in
muscle- and liver-specific AIF deletion (AifD),
confirmed here by PCR and (D) Western blot.
Target tissue isolations and histological analy-
sis by H&E staining showed normal tissue and
cellular morphology in both MAIFKO (E) and
LAIFKO (F) mice. (G and H) Microarray analyses
of targeted tissues from 8-week-old MAIFKO
and LAIFKO mice revealed coordinate down-
regulation of genes of oxidative metabolism.
These reductions overlapped in >85% of cases
with human orthologs reported previously to be
downregulated in humans with insulin resis-
tance (OxPhos) (Mootha et al., 2003; Patti
et al., 2003) and (I) with individual complexes
of the electron transport chain. (J) Gene-ontol-
ogy-based analysis confirmed that of 272
curated pathways (KEGG/BioCarta), OxPhos
and ATP synthesis are two of the three most
significantly modulated pathways in both mus-
cle and liver after AIF deletion. The product
score is a measure of deviation of pathway
expression combined for both the muscle and
liver data sets.Examination of functional markers of OxPhos confirmed
the defects with an increase in NADH/NAD+ ratios and
decreased ATP and cAMP levels in both MAIFKO and
LAIFKO knockout tissues (Figures 2C and 2D; Figure S3D).
Plasma lactate, a marker of anaerobic metabolism, was
found to be modestly elevated in MAIFKO and LAIFKO478 Cell 131, 476–491, November 2, 2007 ª2007 Elsevier Inc.mice, corroborating the finding of reduced OxPhos func-
tion in vivo (Tables S3 and S4).
The third criterion necessary to model the OxPhos de-
pendency of insulin resistance is dissociability of OxPhos
modulation from ROS generation. ROS are byproducts of
electron flux through OxPhos and are metabolites known
to cause insulin resistance (Balaban et al., 2005; Houstis
et al., 2006; St-Pierre et al., 2006). Produced primarily at
complex I (directed internally) and complex III (directed
externally), the generation of ROS is dependent on the
rate of flux through the respiratory chain as well as the de-
gree of distal restrictions to electron flow (Adam-Vizi and
Chinopoulos, 2006). Direct measurement of mitochondrial
ROS production using EPR-spectroscopy revealed no
significant changes in either internally or externally gener-
ated ROS in preparations from MAIFKO or LAIFKO mice
(Figures 2E and 2F). These findings were corroborated
by a lack of detectable change in the ROS markers cata-
lase, protein carbonylation, and lipid peroxidation (Figures
S3E–S3G). Western blot analysis of the ROS- and inflam-
mation-responsive signals JNK, IkB, and ERK5 (Nakano
et al., 2006) showed no alteration in either muscle- or
liver-specific AIF knockout mice at 8 weeks of age (data
not shown). No histological signs of inflammation, nor
increased serum levels of the inflammatory cytokines
IL-6 and TNF-a were observed. These findings suggest
that loss of AIF does not cause either ROS accumulation
or the induction of inflammation. Thus, tissue-specific
AIF deletion satisfies all three criteria of moderate, gener-
alized, and ROS dissociable OxPhos reduction providing
a model to test whether primary defects in mitochondrial
respiration cause insulin resistance and obesity.
Enhanced Respiratory Control and Altered
Substrate Access in AIF-Deficient Mitochondria
Changes in OxPhos should be reflected by modifications
in ROS generation unless (1) the balance between respira-
tory coupling and uncoupling is altered, or (2) the access
of electrons to sites of ROS generation is modified by al-
ternate electron entry into the respiratory chain. Isolated
MAIFKO and LAIFKO mitochondria were examined for
their inherent coupling capacity and substrate selectivity.
O2-consumption in AIF-deficient mitochondria was more
efficiently reduced by addition of the ATPase inhibitor
oligomycin than in controls, indicating electron transport
is more tightly coupled to ATP-synthesis in the absence
of AIF (Figures 2G and 2H). Further, reduced O2-con-
sumption rates measured subsequent to addition of the
mitochondrial uncoupler mC1-CCP (carbamoyl cyanide
m-chlorophenylhydrazone) highlighted the decreased ac-
tivity of the OxPhos chain in AIF-deleted mitochondria
(Figure 2G). Interestingly, parallel measurements of sub-
strate selectivity revealed a preference for non-complex-I
electron donors such as succinate (complex II) and
glycerol-3-phosphate (G3P) in AIF deficient mitochondria
(Figure 2I; Figure S3H). These findings were corroborated
by measured increases in succinate-cytochrome c reduc-
tase (SCCR) and glycerol-3-phosphate-cytochrome c
reductase activities (GCCR) in both muscle and liver
mitochondria of AIF knockout mice (Figure S3I). Thus,
AIF ablation reduces complex-I derived electron transfer
and mitigates ROS generation through increased respira-
tory chain coupling.Targeted Deletion of AIF in Muscle Results
in Improved Glucose Tolerance
and Insulin Sensitivity
Since at 8 weeks of age both models demonstrated con-
sistent OxPhos deficiency with no indication of elevated
ROS levels, this time point was chosen for all subsequent
metabolic analyses. Intriguingly, initial metabolic analyses
revealed an improvement in oral glucose tolerance in
MAIFKO mice (Figure 3A, top). Reduced fasting and chal-
lenged blood glucose levels observed during oral glucose
tolerance testing (OGTT) occurred concomitantly with re-
duced insulin secretion suggestive of an increase in insulin
sensitivity (Figure 3A, bottom). In line with these findings,
blood glucose and insulin levels were reduced during nor-
mal feeding cycles (Table S3). Moreover, intraperitoneal
insulin challenge resulted in enhanced blood glucose
lowering in MAIFKO mice (Figure 3B). To validate these
indications of increased insulin sensitivity, a euglycemic-
hyperinsulinemic clamp was performed. Upon infusion
of insulin, MAIFKO mice displayed an immediate and
robust increase in glucose demand (Figure 3C). This in-
crease in insulin sensitivity was characterized by elevated
steady-state (measured between 150 and 180 min) glu-
cose turnover (Figure 3D) as well as augmented glycogen
synthesis rates (Figures 3E and 3F) and a tendency toward
increased hepatic glucose production and whole body
glycolysis (Figures S4A and S4B). Thus, ablation of AIF
in muscle elicits an insulin-sensitive state.
Introduction of radiolabeled 2-deoxyglucose into the
clamp protocol revealed increased glucose flux into all skel-
etal muscles tested but not the heart, skin, liver, or brown
adipose tissue (BAT) (Figure 3G). To link the increased glu-
coseuptake tocriticalnodes in the insulin signalingcascade
(Taniguchi et al., 2006), western blot analysis on muscle ex-
tracts from insulin-clamped animals was performed. Phos-
phorylation of Akt, ERK1/2, and GSK3b were increased in
MAIFKO mice following insulin infusion (Figure 3H, right
panels; Figure S4C). Interestingly, despite reduced fasting
insulin levels (Table S3), ERK1/2 and GSK3b were also in-
creased under fasting conditions (Figure 3H, left panels;
Figure S4C), indicating increased basal activation of insulin
signaling. Also, expression of the two primary muscle glu-
cose transporters GLUT1 and GLUT4 was upregulated in
MAIFKO mice (Figure 3I). Examination of the key metabolic
regulator AMPK revealed increased activation of this AMP
sensor with no apparent change in AMPK protein expres-
sion (Figure 3J). Thus, AIF-deletion in muscle causes
improved insulin sensitivity characterized by increased
muscle glucose uptake, enhanced insulin signaling, and
general upregulation of glucose uptake machinery.
MAIFKO Mice Are Resistant to Diet-Induced
Obesity and Diabetes
In humans and wild-type mice, high fat diet induces
obesity, insulin resistance, and diabetes (Lazar, 2005).
MAIFKO and littermate control mice were challenged
with a high-fat diet from weaning and analyzed at 8 weeks
of age. Control mice fed a high-fat diet developed obesityCell 131, 476–491, November 2, 2007 ª2007 Elsevier Inc. 479
Figure 2. Tissue-Specific Deletion of AIF in Muscle and Liver Results in OxPhos Defects
(A and B) Reductions in OxPhos gene expression were confirmed on the (A) protein and (B) functional levels in both MAIFKO and LAIFKO target
tissues (NDUFx, complex I subunits; UQCRC2, complex III subunit C2; COX4, complex IV subunit 4; CYT C, cytochrome c). AIF expression is shown
as a control for genotypes, and actin is shown as a loading control. OxPhos activities of individual respiratory complexes were assessed on isolated
mitochondria by spectrometry and polarography.480 Cell 131, 476–491, November 2, 2007 ª2007 Elsevier Inc.
as determined by progressive weight gain (Figure 4A), in-
creased lipid accumulation in adipocytes (Figure 4B), and
enhancedfatpadmass (Figure4C).However,despiteasig-
nificant elevation in food intake (Figure 4D), MAIFKO mice
failed to gain additional weight or to accumulate lipids rel-
ative to normal chow fed mutants (Figures 4A–4C). Consis-
tent with the reduction in adipose mass, plasma leptin
levels in MAIFKO mice were markedly decreased (Fig-
ure 4E). We failed to observe alterations in lipid handling
in MAIFKO mice whether by plasma cholesterol, triglycer-
ide, or free fatty acid (FFA) determination (Table S3) or by
measurement of free fatty acid release in response to fast-
ing (Figure S4D). Moreover, indirect calorimetryand activity
measurements did not reveal overt alterations in metabolic
rate, respiratory quotient (nutrient partitioning), activity, or
energy expenditure in MAIFKO animals (Figure S5A–S5C).
In addition to the development of obesity, control mice
fed a high-fat diet develop diabetes defined by fasting hy-
perglycemia and hyperinsulinemia as well as increased
glucose and insulin levels after an oral glucose challenge
(Figures 4F–4H). MAIFKO mice resisted the diabetogenic
effects of the high fat diet (Figures 4F–4H). As evidenced
by a moderate increase in glucose-challenged insulin
levels in MAIFKO mice on high-fat chow, some metabolic
deterioration was still observed in these tissue-specific
mutants (Figure 4G). Importantly, whereas littermate con-
trols exhibited insulin resistance, MAIFKO mice were still
sensitive to the glucose-lowering effects of insulin (Fig-
ure 4I). Thus, muscle-specific ablation of AIF prevents
diet-induced obesity and diabetes.
Improved Metabolic Phenotypes in AIF
Mosaic Mice
We have previously reported that muscle specific AIF
knockout mice eventually succumb to muscle wasting
and dilated cardiomyopathy (Joza et al., 2005). To eliminate
the possibility of experimental bias from these alternate pa-
thologies, we exploited localization of theAIFgene on the X
chromosome (Susin et al., 1999) to generate a set of mice
with a mosaic muscle-specific AIF knockout pattern based
upon random epigenetic X-inactivation (AIFflox/+; Mck-cre/
+). These mice exhibit mosaic expression of wild-type or
deleted AIF alleles in muscle and, beyond 8 months of
age, continue to grow normally and show no evidence of
muscle wasting, cachexia, or cardiomyopathy (Figure 5A;
data not shown). Importantly, these mosaic mice recapitu-
late the lean phenotype of muscle-specific AIF null animals(Figures 5B and 5C). Moreover, determination of glucose
handling showed that AIF mosaic mice exhibit improved
glucose tolerance and reduced insulin levels (Figures 5D–
5F). Similar to MAIFKO mice, metabolic rate, respiratory
quotient, activity, and energy expenditure were compara-
ble between mosaic MAIFKO and control littermates (Fig-
ures S5D–S5F). These results dissociate possible influ-
ences from secondary pathologies over the long term and
confirm that inactivation of AIF in muscle cells can protect
from weight gain and insulin resistance.
Liver-Specific AIF Knockout Mice Are Glucose
Tolerant and Resist Obesity and Diabetes
In addition, the liver has been implicated in the develop-
ment of insulin resistance and demonstrated OxPhos
changes in humans (Misu et al., 2007). Examination of glu-
cose control by OGTT in liver-specific AIF knockout
(LAIFKO) mice, similar to MAIFKO animals, revealed
marked improvements in glucose tolerance characterized
by decreases in both peak blood glucose and insulin levels
relative to control animals (Figure 6A). Also, LAIFKO mice
displayed a hyper-responsiveness to i.p. insulin injection
(Figure 6B). In euglycemic-hyperinsulinemic clamp stud-
ies, LAIFKO animals required increased glucose infusions
(GIR) (Figures 6C and 6D) and exhibited significantly in-
creased glucose turnover (Figure 6D). Hepatic glucose
production remained unchanged (Figure 6D). Consistent
with increased anaerobic metabolism, we observed in-
creased glycolysis (Figure 6D). Considering the age-de-
pendence of diabetes and obesity as well as the progres-
sive nature of OxPhos deficiencies (Lowell and Shulman,
2005; Wallace, 1999), we asked whether the glucose toler-
ant LAIFKO phenotype would change with time. Glucose
tolerance tests performed at 8, 16, and 52 weeks of age
showed significant improvements in glucose tolerance of
LAIFKO mice at all ages (Figure 6E), indicating that in-
creased insulin sensitivity was maintained with aging. In-
triguingly, despite a reduction in plasma insulin levels after
fasting (Table S4), the critical insulin signaling components
ERK1/2 and GSK3b again showed heightened activation in
the knockout animals (Figure 6F). In addition, expression of
the glucose transporter GLUT1 levels as well as activation
of AMPK and expression of nutrient sensor SIRT1 were in-
creased in vivo (Figure 6F). Thus, loss of AIF expression in
hepatocytes results in increased insulin sensitivity.
We next examined whether liver-specific loss of AIF
would render mice resistant to high-fat feeding. Whereas(C and D) Decreases in relative NAD+ and ATP levels served as a functional readout of the cellular consequences of reduced OxPhos in both MAIFKO
and LAIFKO mice.
(E and F) Direct measurement of ROS generation in isolated target tissue mitochondria by EPR-spectroscopy showed no elevation in ROS levels in
either MAIFKO or LAIFKO mice. Measurements of ROS production both inside and outside the mitochondria were made using the spin trap CPH (total
ROS). ROS produced externally were evaluated using the membrane impermeable spin trap PPH (external). Internally generated ROS production was
determined by subtraction (internal).
(G and H) Mitochondria isolated fromAIF-deficient muscle and liver displayed increased respiratory coupling relative to controls when assessed using
polarography.
(I) Spectrophotometric analysis revealed altered substrate preference through monitoring of substrate competition between NADH oxidation and
oxidation of succinate or glycerol-3-phosphate. All measures were made using 8-week-old mice. AIFflox/y mice served as controls. All data are
mean ± SEM. n = 4–9 per group. *p < 0.05 versus control.Cell 131, 476–491, November 2, 2007 ª2007 Elsevier Inc. 481
Figure 3. Targeted-Ablation of AIF in Muscle Causes Improved Glucose Tolerance and Insulin Sensitivity
(A) Relative to all three control littermate genotypes (wild-type, Mck-cre hemizygote, andAIFflox/y), MAIFKO mice exhibit reduced blood glucose levels
and reduced plasma insulin excursions in response to a 1 g/kg oral glucose load.
(B) Bolus injection of insulin intraperitoneally elicits a more profound glucose reduction in MAIFKO mice relative to littermate controls.
(C) Plasma glucose and glucose infusion rates, measured during a euglycemic hyperinsulinemic clamp, reveal increased insulin-induced glucose
demand in MAIFKO mice.
(D–F) The measured increase in insulin sensitivity was characterized by increased whole-body glucose turnover as well as increased whole body and
muscle specific- glycogen synthesis.
(G) Including labeled 2-deoxyglucose into the clamp protocol revealed enhanced glucose uptake in skeletal muscle depots of mutant mice (EDL,
extensor digitorus longus; Sol, soleus; VL, vastus lateralis; BAT, brown adipose tissue; WAT, white adipose tissue). Data in (A)–(G) are mean ±
SEM. n = 8–10 per group. *p < 0.05 versus littermate controls.
(H) Consistent with the observed increases in insulin sensitivity, enhanced phosphorylation of ERK1/2, Akt, and GSK3b were observed in both fasted
and insulin stimulated (clamped for 3 hr) muscle tissue by western blotting.
(I) Protein expression of the glucose transporters 1 and 4 (GLUT1 and GLUT4) were increased in MAIFKO muscle.
(J) Elevated AMPK phosphorylation in muscle of MAIFKO mice. In (H)–(J), data pooled data (2 mice per lane) from four individual control and four
individual MAIFKO mice are shown. b-Actin is shown as a loading control. All animals were 8 weeks of age. Controls are AIFflox/y.482 Cell 131, 476–491, November 2, 2007 ª2007 Elsevier Inc.
Figure 4. MAIFKO Mice Are Resistant to
Diet-Induced Obesity and Diabetes
(A) High-fat feeding (HF; open symbols) pro-
motes adiposity in control, but not MAIFKO,
animals. Closed symbols are from mice fed
with normal chow (NC). Mice were fed a high-
fat diet from 3 to 8 weeks of age at which
time all presented metabolic analyses were
performed.
(B–C) Reduced development of adiposity was
seen at the cellular level by H&E staining as
well as by determination of white (perigonadal;
WAT) and brown adipose tissue (BAT) masses
after both normal chow and high-fat diet. Data
in (C) are shown as knockout tissue mass rela-
tive to control tissue mass.
(D) Reduced adiposity in MAIFKO mice oc-
curred despite increased food intake. Food in-
take was determined over 48 hr in metabolic
cages.
(E) Consistent with reduced fat mass, circulat-
ing leptin levels were reduced in MAIFKO ani-
mals relative to control littermates. Food intake
was determined over 48 hr in metabolic cages.
(F–H) Oral glucose tolerance testing revealed
maintenance of the glucose tolerant and insulin
sensitive state after high-fat feeding. AUC, area
under the curve.
(I) An insulin tolerance test showed a clear sep-
aration in the ability of MAIFKO mice to clear
glucose after a defined insulin load (1.5 U/kg
i.p.). Data are mean ± SEM. n = 6–10 animals
per group. *p < 0.05 versus control. Controls
are AIFflox/y. NC, normal chow diet; HF, high-
fat diet; WAT, white adipose tissue; BAT,
brown adipose tissue.control mice gained 17% body weight over this time frame
of high-fat feeding, LAIFKO mice gained only 2% relative
to normal chow fed LAIFKO mice (Figure 7A). Measure-
ment of epididymal fat pad weights confirmed marked ad-
ipose deposition in control animals with no discernable
impact on the knockout animals (Figures 7B–7D). The de-
scribed resistance to adipose deposition occurred de-
spite an increase in food intake. Food intake in normal
chow fed LAIFKO mutants was also moderately elevated
(Figure 7E). The metabolic rate, respiratory quotient, activ-
ity, and energy expenditure were comparable between
mosaic MAIFKO and control littermates (Figures S5G–
S5J). No obvious differences in differentiation and func-
tional markers of brown and white adipose tissue weredetected in either MAIFKO or LAIFKO mice at the tran-
scriptional level (Figures S6A and S6B). In addition, an
examination of intracellular lipids in muscle and liver tis-
sues of AIF mutant mice revealed no overt changes in tri-
glyceride (Figures S7A and S7B) or long chain fatty acyl
CoA’s (Figures S7C and S7D). These data suggest that
the lean phenotype of muscle or liver specific AIF mutant
mice does not result from overt changes in adipose tissue
reprogramming.
When tested for glucose tolerance after chronic high-fat
feeding, control mice exhibited increased blood glucose
and insulin levels. By contrast, glucose and insulin values
in high fat fed LAIFKO mice remained comparable to those
of chow fed controls (Figure 7F). While some metabolicCell 131, 476–491, November 2, 2007 ª2007 Elsevier Inc. 483
Figure 5. Mosaic Patterning of the AIF Deletion in Muscle Improves Glucose Tolerance
(A) To circumvent the premature mortality exhibited by MAIFKO mice, mice were generated exhibiting mosaic patterning of theAIF deletion in muscle.
Since AIF is located on the X chromosome, cre-bearing AIFflox/+ female heterozygotes will alternately exhibit either wild-type or deleted AIF as a con-
sequence of random X-inactivation. These mice are born and grow normally and exhibit no obvious pathologies up to and beyond 8 months of age.
(B and C) Measurement of body weight and body mass index (BMI) in these mice confirmed the lean phenotype. BMI (body mass index) = [weight (g)/
length2 (cm2)].
(D) Oral glucose tolerance testing (1 g/kg) in 6-month-old mosaic mice reveals a moderate improvement in glucose tolerance with a considerable
reduction in peak insulin levels.
(E and F) Reductions in blood glucose and plasma insulin levels appeared progressive, with a trend already obvious at 2 months of age (i.e., prior to
any changes in body weight). Data are mean ± SEM. n = 6 animals per group. *p < 0.05 versus control.deterioration was observable, e.g., increased insulin rela-
tive to chow-fed LAIFKO animals (Figure 7F), insulin toler-
ance testing further confirmed that LAIFKO mice maintain
an insulin sensitive phenotype even after high-fat feed-
ing (Figure 7G). As with the MAIFKO mice, we failed to
observe altered lipid handling in the LAIFKO mouse (Fig-
ure S7; Table S4). Thus, deletion of AIF in the liver, similar
to muscle-specific deletion, induces a lean and insulin
sensitive metabolic state, conferring resistance to the
adipogenic and diabetogenic effects of hypercaloric
feeding.
Improved Insulin Sensitivity in Mice
with a Ubiquitous OxPhos Defect
To examine the possibility that a multisystem OxPhos de-
fect, rather than a muscle- or liver-specific deficiency,484 Cell 131, 476–491, November 2, 2007 ª2007 Elsevier Inc.may account for the correlative development of insulin re-
sistance in human subjects (Dahlman et al., 2006), we an-
alyzed a global model of OxPhos deficiency, the harlequin
mouse (Hq). While ubiquitous disruption of the Aif-allele is
embryonic lethal (Joza et al., 2005), AIF-hypomorph Hq
mice manifest a proviral intron insertion in the AIF gene
as an ubiquitous 80% reduction in AIF protein expression
and associated AIF-dependent OxPhos defects (Vahsen
et al., 2004; van Empel et al., 2005). Similar to both mus-
cle- and liver-specific AIF mutants, AIF-hypomorph Hq
mice were resistant to the progressive weight gain and
lipid accumulation associated with high-fat feeding (Fig-
ures 8A and 8B). Food intake was increased in the Hq
mice (Figure 8C). Moreover, relative to littermate controls,
Hq mice displayed improved glucose tolerance associ-
ated with reduced fasting and glucose-induced insulin
Figure 6. Improved Glucose Disposal
and Insulin Sensitivity after AIF Deletion
in a Second Insulin-Responsive Tissue,
the Liver
(A) Relative to the three control littermate
genotypes (wild-type, Alb-cre hemizygote,
and AIFflox/y), LAIFKO mice exhibited reduc-
tions in plasma glucose and insulin levels after
a 1 g/kg oral glucose challenge.
(B) LAIFKO mice exhibit an exacerbated hypo-
glycaemic response to intraperitoneal insulin
(0.75 U/kg) relative to littermate controls.
(C) In response to a 4 mU/min/kg chronic
insulin infusion, LAIFKO mice required a signif-
icantly increased glucose infusion (GIR) rela-
tive to Control mice in order to maintain
euglycemia.
(D) The measured increase in insulin sensitivity
was characterized by increased whole-body
glucose turnover, increased GIR, increased
glycolysis, and no change in hepatic glucose
production (HGP). There was a tendency,
albeit not significant, toward increased glyco-
gen synthesis.
(E) Evidence of increased insulin sensitivity
provided by oral glucose tolerance tests
(OGTTs) that was maintained at least up to 1
year of age in LAIFKO mice. Data in (A)–(E)
are mean ± SEM. n = 6–12 per group. *p <
0.05 versus littermate controls.
(F) Increased phosphorylation of the key insulin
signaling intermediates ERK1/2, Akt, and
GSK3b were observed in fasted LAIFKO livers.
Also observed by western blotting were
increases in expression of GLUT1 and SIRT1,
as well as phosphorylation of the AMP-respon-
sive AMPK. b-Actin is shown as a loading
control. C, Control; KO, LAIFKO. All animals
were 8 weeks of age unless otherwise indi-
cated. Controls are AIFflox/y.secretion (Figure 8D). These indications of improved insu-
lin sensitivity in Hq mice were confirmed using an insulin
tolerance test (Figure S8A). Importantly, Hq mice also
displayed virtually complete resistance to diet-induced
diabetes (Figure 8D; Figure S8B). We confirmed these
data at several ages up to 8 months (data not shown),
a time point after which the neurodegenerative effects of
global OxPhos defects begin to surface in the Hq mouse
(van Empel et al., 2005). Thus, the generalized OxPhos
deficit in the Hq mouse does not predispose toward insu-
lin resistance and results in a diabetes- and obesity-resis-
tant metabolic phenotype.
ImprovedGlucose Tolerance of AIF-DeficientMice
Is Both Inducible and Reversible
To address the causality of AIF modulations on mitochon-
drial function and glucose tolerance, we designed two
adenoviral transgene delivery protocols to induce and res-cue the observed phenotypes. First, we performed AIF
gene ablation in 7 week old adult AIFflox/flox mice using ad-
enoviral delivery of Cre recombinase. As reported previ-
ously for other floxed alleles (Lee et al., 1997) adenovi-
rus-Cre resulted in predominant deletion of AIF in the
liver (Figure S8C). Within 2 weeks we observed marked
downregulation of AIF protein expression (Figure 8E) and
impaired mitochondrial function as determined by re-
duced complex I activity (Figure 8F). Importantly, when
challenged with glucose, mice with such acute deletions
of AIF exhibited both markedly reduced peak blood
glucose (Figure 8G) and decreased plasma insulin levels
(Figure 8H).
We next performed an in vivo rescue experiment to test
the reversibility of the AIF phenotype. A cohort of LAIFKO
mice was injected with adenoviruses carrying a wild-type
AIF transgene. In vivo delivery of AIF indeed increased AIF
protein levels in the liver of LAIFKO mice (Figure 8I).Cell 131, 476–491, November 2, 2007 ª2007 Elsevier Inc. 485
Figure 7. Liver-Specific AIF Knockout
Mice Are Resistant to Obesity and
Diabetes
(A) LAIFKO mice are spared from the weight
gain associated with chronic high-fat feeding.
(B–D) Fat deposition is reduced in 8-week-old
LAIFKO mice both after normal chow feeding
and after 5 weeks of a high-fat diet. Sol/
Gast., soleus and gastrocnemius; WAT, white
(perigonadal) adipose tissue; BAT, brown
adipose tissue.
(E) The observed reductions in adiposity of
LAIFKO mice occur despite significant in-
creases in food intake. Food intake was mea-
sured over 48 hr in metabolic cages.
(F) A 1 g/kg OGTT revealed that LAIFKO mice
resist the diabetogenic effects associated
with a hypercaloric feeding. OGTTs were per-
formed on 8-week-old mice, after 5 weeks of
high-fat feeding.
(G) High-fat fed LAIFKO mice maintain an
increase in insulin sensitivity following an i.p.
insulin challenge (1.5 U/kg). Data are mean ±
SEM. n = 6–10 animals per group. *p < 0.05
versus control. All mice were 8 weeks of age.
Controls are AIFflox/y.Remarkably, expression of transgenic AIF elicited a ro-
bust rescue of glucose tolerance (Figure 8J). In addition,
plasma peak insulin levels were restored to near normal
in LAIFKO mice 1 week after delivery of the wild-type
AIF transgene (Figure 8K). These data show that acute
changes in AIF expression can both induce and reverse
mitochondrial dysfunction and, most importantly, improve
glucose tolerance in mice.
DISCUSSION
To test the hypothesis that reduced OxPhos causes insu-
lin resistance, we needed to develop a genetic model
system that closely mimicked previously reported OxPhos
defects in prediabetic humans. We therefore generated
and tested the applicability of muscle- and liver- specific
AIF knockout mice. Three criteria were used: the model
should demonstrate a (1) mild, (2) generalized, and (3)486 Cell 131, 476–491, November 2, 2007 ª2007 Elsevier Inc.ROS-dissociable OxPhos deficit. Using protein and RNA
analyses coupled with functional biochemistry in mito-
chondria, we established that MAIFKO and LAIFKO mice
display subtle reductions in expression of OxPhos genes
from all respiratory chain complexes. These changes
were manifest functionally in both muscle- and liver-spe-
cific knockouts and overlap >90% with the human data
sets first identifying coordinate downregulation of OxPhos
genes as a potential cause of insulin resistance (Mootha
et al., 2003; Patti et al., 2003). In addition to a coordinate
reduction in OxPhos gene expression, examination of iso-
lated AIF-deficient mitochondria revealed a tightening of
respiratory control and shifted substrate selectivity culmi-
nating in an OxPhos deficiency dissociable from ROS
accumulation, suggesting a novel role for AIF in the control
of electron flow through the respiratory chain. Thus, using
AIF-conditional mutant mice, we asked whether a primary
OxPhos defect triggers insulin resistance and diabetes
Figure 8. Insulin-Sensitive States Re-
sulting from AIF Deletion Are Inducible,
Reversible, and Maintained under
Ubiquitous Hypomorph Conditions
Relative to littermate controls (gray squares),
the ubiquitous Aif-hypomorph, the harlequin
mouse (blue circles), demonstrates a nearly
identical metabolic phenotype to MAIFKO
and LAIFKO mice with reduced (A) body weight
and (B) perigonadal adipose deposition in
response to high-fat feeding (open symbols)
despite (C) hyperphagia. (D) Harlequin mice
exhibit greatly improved glucose tolerance in
response to a 1 g/kg oral glucose load. (E–K)
Seven-week-old AIFflox/flox mice were adminis-
tered 2 3 109 pfu of either Adeno-Cre or
Adeno-GFP in PBS via the tail vein. (E) Robust
decreases of AIF protein level were detectable
in Adeno-Cre-induced liver relative to controls
(Adeno-GFP). (F) Liver samples obtained from
Cre-induced animals exhibited significant de-
creases in Complex I activity. (G and H) Oral
glucose tolerance (1 g/kg) showed significant
improvement in both (G) glucose and (H)
insulin levels consistent with increased insulin
sensitivity. (I) Parallel i.v. administration of
Adeno-AIF into LAIFKO mice significantly
raised AIF protein levels in the liver compared
to Adeno-GFP treated LAIFKO littermate
controls. (J) Within 1 week after transgene
delivery the Adeno-AIF group displayed signif-
icantly elevated fasting and peak blood glucose levels during an OGTT and (K), similarly, increases in peak plasma insulin. Data are mean ± SEM.
n = 6–10 animals per group. *p < 0.05 versus control normal chow, #p < 0.05 versus high-fat diet fed controls. NC, normal chow diet; HF, high fat
diet. All mice were 8 weeks of age.and, importantly, dissociates these phenotypes from the
interference of ROS accumulation.
We have previously reported cardiomyopathy and mus-
cle wasting at late stages in the muscle-specificAIF knock-
outs (Jozaet al., 2005; Wanget al., 2001; Wanget al., 1999).
To rule out potential interference of such alternate patholo-
gies in MAIFKO mice, numerous measures were under-
taken. First, backcrossing the conditional AIF mouse onto
the C57BL/6 background slowed the manifestation of the
OxPhos defect and associated myopathies significantly;
8-week-old MAIFKO mice showed no measurable mor-
phological, histological, serum, or intracellular signaling
signs of muscle wasting, cardiomyopathy, or associated
cachexia. MAIFKO showed normal heart-weight ratios at
8 weeks of age, displayed normal glucose uptake in the
heart in vivo, and contrary to predictions for a (pre-)cachec-
tic state, food intake was increased. We also exploited
AIF’s presence on the X chromosome to generate a set of
mice with a mosaic muscle-specific AIF knockout pattern
based upon random epigenetic X-inactivation (AIFflox/+;
Mck-cre/+). These mice live long, full lives with no signs
of muscle wasting or cardiomyopathy. As a final genetic
control to exclude alternate pathologies, we performed
AIF gene ablation in 7-week-old adult AIFflox/flox mice using
adenoviral delivery of Cre recombinase and an in vivo res-
cue experiment to test the reversibility of the AIF pheno-
type. Acute changes in AIF expression could indeed induceand reverse mitochondrial dysfunction and, most impor-
tantly, improve glucose tolerance in adult mice in vivo.
To date, a number of studies have linked reduced mito-
chondrial oxidative metabolism to the development of in-
sulin resistance in humans (Lowell and Shulman, 2005;
Wisløff et al., 2005; Rabol et al., 2006; Mootha et al.,
2003; Patti et al., 2003), though none have demonstrated
a causal link. In addition, a recent study using a pharmaco-
logical approach suggested that improving mitochondrial
function protects from diabetes and obesity (Lagouge
et al., 2006). Mechanistically, it is proposed that insulin re-
sistance caused by reduced OxPhos results from the ac-
cumulation of metabolites such as ROS and long chain
fatty acids which then cause insulin resistance (Lowell
and Shulman, 2005). Although we cannot exclude that
specific patterns of OxPhos dysfunction may be causative
for insulin resistance, our data show that a mild and gen-
eralized OxPhos deficit absent of ROS generation can cul-
minate in a state of reduced adiposity and increased insu-
lin sensitivity, an important contradiction of the current
dogma. Similar to human studies correlating OxPhos
and insulin resistance across a range of ages (Petersen
et al., 2003, 2004) our data in young and old mice indicate
that the beneficial effects of defective OxPhos appear to
be independent of age. Support for our findings was
recently provided by a study showing that mice carry-
ing a muscle-specific deletion of the mitochondrialCell 131, 476–491, November 2, 2007 ª2007 Elsevier Inc. 487
transcription factor Tfam do not develop insulin resistance
(Wredenberg et al., 2006). Tfam controls expression of all
mitochondrial encoded genes including those coding for
numerous OxPhos subunits, and its deletion is well ac-
cepted to cause marked respiratory deficiency. While
the previously reported effects of tfam deletion such as
ROS generation, muscle atrophy, or body weight were
not examined, this study supports the data presented
here, questioning a causal role for OxPhos reductions in
the development of insulin resistance (Wang et al., 1999,
2001; Wredenberg et al., 2006).
How might such an OxPhos-dependent compensatory
mechanism work? The OxPhos reductions observed
in MAIFKO and LAIFKO mice produce three primary me-
tabolite shifts (decreased ATP, decreased NAD+, and in-
creased AMP) and promote anaerobic glucose meta-
bolism. To compensate for the relative inefficiency of
anaerobic metabolism and aerobic substrate shifts, a
net increase in fuel utilization (glucose and fatty acid me-
tabolism) is required to meet energy demands. This ineffi-
cient utilization of fuels likely accounts for the failure of our
OxPhos-deficient mice to increase their fat body mass
even in the context of increased caloric intake. Further-
more, activation of AMPKinase stimulates catabolic pro-
cesses such as glucose uptake and fatty-acid oxidation
(Towler and Hardie, 2007). Finally, reduced NAD+ levels,
observed in both MAIFKO and LAIFKO mice, have been
shown to reduce activation of the SIRT1/PGC1a pathway
promoting glycolysis and, thus, exacerbating the anaero-
bic phenotype (Rodgers et al., 2005). These effects coin-
cide precisely with the observed metabolic changes in
AIF deficient mice, namely increased glucose utilization,
increased glycolysis, and reduced lipid storage. Thus,
our data imply that a primary OxPhos defect results in
increased glucose uptake and enhanced fuel utilization.
Recent studies have placed altered mitochondrial oxi-
dative phosphorylation in muscle and liver as an underly-
ing genetic element of insulin resistance (Lowell and Shul-
man, 2005; Misu et al., 2007; Mootha et al., 2003; Patti
et al., 2003; Petersen et al., 2003, 2004; Rabol et al.,
2006). However, the causative or compensatory nature
of these OxPhos changes has never been experimentally
proven. Our data in four different mouse models of tissue
specific and global OxPhos deficiency show that a primary
OxPhos defect alone does not cause diabetes but, rather,
can result in increased insulin sensitivity and resistance to
diabetes and obesity. Importantly, acute induction and
rescue experiments indicate a causal link between AIF-
modulation and insulin sensitivity, absent of secondary
body weight compensations. These findings carry pro-
found implications for basic physiology and the develop-
ment of future antidiabetic therapies.
EXPERIMENTAL PROCEDURES
Generation of Tissue-Specific AIF Knockout Mice
Mice with a conditional Aif allele were generated by homologous
recombination (Joza et al., 2005). Aifflox mice were backcrossed >8488 Cell 131, 476–491, November 2, 2007 ª2007 Elsevier Inc.times onto the C57/Bl6 background prior to initiation of the current
studies. Mice with a targeted deletion of AIF in striated muscle were
generated by crossing the Aifflox/+ mice with transgenic mice express-
ing Cre-recombinase under the control of the muscle creatine kinase
promoter (Mck-cre) (Bruning et al., 1998). Aifflox/+ female mice bearing
the cre-transgene established a second model, one of mosaic AIF de-
letion in striated muscle due to random expression of either the floxed
or WT allele in any single myocyte. Crossing the conditional line to mice
expressing Cre-recombinase under control of the Albumin promoter
yielded the third model, liver-specific AIF knockout mice. Harlequin
mice were obtained from Jackson Laboratories (USA). Normal chow
(6% fat; M-Z, energy rich) and high-fat (30% fat; EF1/22) diets were
obtained from Ssniff GmbH, Germany. Mice were fed the high-fat
diet starting from 3 weeks of age until termination of the experiments.
Animals were kept on a 12 hr light/dark cycle and housed at the IMBA
Animal Facility in accordance with institutional guidelines.
Assessment of Mitochondrial Function
For the isolation of mitochondria, hindlimb muscle, or total liver from
MAIFKO or LAIFKO mutant mice and their respective and littermate
controls were homogenized (250 mM sucrose, 5 mMTris-HCl, 2 mM
EGTA [pH 7.2]) at 4C. Homogenate was centrifuged at 760 3 g for
10 min at 4C to remove nuclei and cellular debris. The supernatant
was then centrifuged at 8,740 3 g. The pellet was resuspended, lay-
ered onto a 60%–30%–18% sucrose Percoll gradient, and centrifuged
at 8,460 3 g. Activities of complexes I to IV were spectrophotometri-
cally measured using a dual-wavelength spectrophotometer (SLM-
Aminco DW-2A; SLM Instruments, Inc., Urbana, IL) (Chretien et al.,
1994). Measurements of NADH oxidation were performed by polarog-
raphy (Benit et al., 2006).
Glucose and Insulin Tolerance Tests
Following an overnight fast, mice were administered glucose (1 g/kg)
by oral gavage, and blood samples for glucose and insulin determina-
tion were collected from the tail vein at the indicated times. Insulin
tolerance was assessed after a 2 hr fast by administration of human in-
sulin (0.75 U/kg i.p.; 1.5 U/kg after high-fat feeding) and blood glucose
monitoring. Glycemia was assessed using a SureStep Ultra (Lifescan)
glucometer. Insulin determinations were made using a low sample
volume insulin ELISA (Crystal Chemistry).
Hyperinsulinemic Clamps andWhole-Body Glucose Turnover
Hyperinsulinemic clamps were performed as described (Knauf et al.,
2005). In brief, an indwelling catheter was placed into the left femoral
vein and externalised in the interscapular region. The animals were
allowed to recover for 5 days and fasted for 6 hr on the day of the ex-
periment. For 3 hr D-[3-3H]-glucose was infused at a rate of 30 mCi/kg/
min and insulin at a rate of either 4 mU/kg/min (LAIFKO) or 18 mU/kg/
min (MAIFKO and LAIFKO). Low insulin infusions were used to assess
hepatic insulin sensitivity while high insulin was used to assess muscle
insulin sensitivity. Euglycemia was maintained by variable infusion of
15% glucose. Whole blood was sampled from the tail every 10 min
during the last hour. Total radioactivity in the supernatant was deter-
mined by scintillation counting. Total glucose concentrations were
determined by the glucose oxidase method (BioMerieux). Glycogen
content was determined in quadriceps muscle and liver using the amy-
loglucosidase method. Released glucose was determined by a glucose
oxidase method (BioMerieux). Plasma T3, T4, and cortisol levels, as
well as the muscle and liver enzyme panels, were determined by an
analytical laboratory (InVitro, Austria), while the inflammatory markers
TNF-a, IL-6, resistin, as well as leptin, were determined using a multi-
plex kit from Linco Research (USA).
Indirect Calorimetry
Mice were placed for 48 hr in metabolic cages connected to an open-
circuit, indirect calorimetry system combined with the determination of
spontaneous activity by beam breaking (Oxylet, Panlab-Bioseb, Cha-
ville France). The animals were accustomed to the apparatus during
the first 24 hr, followed by measurement for a further 24 hr. Oxygen
consumption and carbon dioxide production were recorded at 5 min
intervals using a computer-assisted data acquisition program (Chart
5.2, AD Instruments, Sydney, Australia).
Tissue Glucose Utilization
Mice were injected with 3H-2 deoxyglucose (Perkin Elmer) through the
intrafemoral catheter one hour before completion of the infusion pro-
cedure (Knauf et al., 2005). Tail blood was sampled at 5, 10, 15, 20,
30, 45, and 60 min after the injection to determine the time course of
3H-2 deoxyglucose disappearance. The 3H-2 deoxyglucose-6-phos-
phate content was determined from NaOH hydrolysed tissues by the
Somogyi procedure (Somogyi, 1945).
Western Blotting
Tissue samples were snap frozen, pulverized, and dispersed in lysis
buffer (0.02 M Tris, 1% NP40, 0.15 M NaCl, 0.15 M NaF, 2 mM
Na3VO4, 5 mM EDTA, + Complete cocktail protease inhibitors). 40 mg
of sample were loaded onto 4%–12% gradient gels (Invitrogen) and
blotted. All antibodies were obtained from Cell Signaling except anti-
bodies for respiratory chain subunits (Molecular Probes), CD36 and
AIF (Chemicon), GLUT1 and GLUT4 (Abcam).
Microarray Analyses
Three independent microarray analyses were performed using hin-
dlimb and total RNA preparations from BMI-matched MAIFKO and
LAIFKO mice and their respective AIFflox/y littermates. Briefly, after
linear amplification and reverse transcription in the presence of Cy3-
dUTP or Cy5-dUTP, cDNA probes were ethanol precipitated together
with poly-dA, tRNA, and mouse Cot.1 DNA. Following posthybridiza-
tion washing (0.23 SSC, 0.1% SDS), the slides were dried and
scanned (Axon GenePix 4000). Results were normalized using the Bio-
conductor marray package, and the ‘‘Print Tip Loess’’ Algorithm. The
cDNA microarrays were compiled and printed from 26,000 EST clones
(BMAP and NIA clones) corresponding to 17,000 Unigene clusters.
Gene ontology-based scoring was performed using pathway sets
curated from the Biocarta and KEGG databases (www.biocarta.com
and http://www.genome.jp/kegg/pathway.html) (Tomfohr et al., 2005).
Determination of Intracellular Metabolites
Measurements of NAD/NADH, ATP, cAMP, catalase, and protein car-
bonylation were determined in freshly isolated hindlimb muscle or liver
from 4, 8, and 16 week old male MAIFKO, LAIFKO, and their respective
controls. NAD/NADH levels were determined by an enzyme cycling
method in acid or base extracted sample (Lin et al., 2001). ATP and
cAMP levels were assessed using commercially available assays
(ATP CLS II, Roche; cAMP [low pH] immunoassay, R&D Systems).
ROS generation was measured directly by EPR-spectroscopy on iso-
lated mitochondria and indirectly using kits for catalase activity, protein
carbonylation, and lipid peroxidation (Cayman Chemicals and Oxis
International, USA). In brief, EPR-spectroscopic detection of ROS gen-
eration was performed by mixing isolated mitochondria with 20 mM of
either of the spin trap compounds, CPH (1-hydroxy-3-carboxy-pyrroli-
dine) or PPH (1-hydroxy-4-phosphonooxy-2,2,6,6-tetramethylpiperi-
dine). EPR measurements were performed on a Bruker EMX EPR spec-
trometer (BioSpin GmbH Rheinstetten/Karlsruhe, Germany).
Histology and Mitochondrial DNA Quantification
Unless otherwise indicated, all tissue samples were obtained from
8-week-old male littermates. Samples for light microscopy were fixed
in 4% PFA for 1 hr. Paraffin embedding, sectioning, and H&E staining
were performed according to standard protocols. Transmission elec-
tron microscopy was performed after a 1 hr fixation in 2% Gluteralde-
hyde/1% PFA in Cacodylate buffer (pH 7.4), and postfixation treat-ments with 1% OsO4 and 1% uranyl acetate. MtDNA content of
muscle was determined by realtime PCR using primers specific for
the murine mitochondrial encoded proteins ND1 (forward: AGGGTAC
ATACAACTACGAAAAGGCC, reverse: GAGTATTTGGAGTTTGAGGC
TCATCC) and COX (forward: TTGGAGGCTTTGGAAACTGACTTG,
reverse: CAGTACGGCTGTAATAAGTACGGATCAG). Values were
related to tubulin as a nuclear DNA control.
Adenoviral Delivery
Adeno-AIF was a kind present from Dr. R. Slack, Ottawa (Canada).
Adeno-Cre and Adeno-GFP were obtained commercially from Vector
Biolabs (USA). All three adenoviral constructs were driven by the CMV
promoter and coded additionally for GFP. Viruses were diluted to
a concentration of 1 3 109 pfu/5 g body weight in 200 ml of PBS and
injected into the tail vein of recipient mice.
Statistical Analysis
All data are shown as mean ± SEM. Measurements at single time
points were analyzed by ANOVA or if appropriate by t test. Time
courses were analyzed by repeated-measurements (mixed model)
ANOVA with Bonferroni post-tests. All statistical tests were calculated
using the GraphPad Prism 4.00 (GraphPad Software, San Diego, CA,
USA). p < 0.05 was considered to indicate statistical significance.
Supplemental Data
Supplemental Data include eight figures and four tables and can be
found with this article online at http://www.cell.com/cgi/content/full/
131/3/476/DC1/.
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